"as FDA have been clear they want another trial" Not true The...

First 9 Last

Share
Profile

Follow
antibotter

7,521 Posts.

263

15/03/19

00:06

Post #: 37768361
Share

Originally posted by stockrock ↑

I believe the timing of the meeting won’t have much bearing on the outcome, as FDA have been clear they want another trial, and SPL will be going into the meeting fighting an uphill battle. Even the most loyal supporters concede that “confirmatory data” is FDA speak for another trial.

The likelihood is that SPL probably won’t get a straight answer in the meeting, and management will need to make a judgement call.

a) Take a risk and resubmit the NDA with the same trial data they believe may address the FDA’s concerns and risk another CRL and lengthy delay; or

b) Be prudent and just run another trial that will 100% meet the FDA’s requirements and guarantee an outcome with the next NDA.

I’d be highly surprised and sceptical if SPL management came out and said it was all good to go, because that is not how the FDA works.

The FDA has a reputation as the toughest pharma regulator in the world for a reason, and they don’t play around with ifs or maybes... they ask for something and they expect a response that clearly meets their requirement.

I eluded to this a couple of times already, but the fact the FDA BV approval requirements are still in draft will give the FDA a lot of room to ask for something “left field” that SPL had not considered when running their phase 3 trials.

Expand

"as FDA have been clear they want another trial"

Not true

The meeting is expected to clarify what confirmatory data will be required and whether the requirement can be satisfied by additional analyses of existing clinical data on hand or, whether this will be through thegeneration of new confirmatory clinical data

Last edited by antibotter: Sll 15/03/19

SPL Price at posting: $1.01 Sentiment: Buy Disclosure: Held
1 Upvote

0 Great analysis

Reply

Top Stories

GRL

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

HotCopper Highlights: Your most watched stocks for Week 46, 2024

LYN

InhaleRX gains approval for clinical trial to test non-opioid therapy for cancer pain

Week 46 Wrap: Copper hits 2mth low as Trump threatens net zero pace; US rally fades; HotCopper’s picks

AN1

CuFe sells its Crossroads gold royalty to Northern Star for $4M cash; says better than waiting for mine launch

AUN

Cyclone signs MOU with Vale for development of Iron Bear play

ME1

Banshee's historic trenches prove rich in antimony and gold for GDM

EDE

NT Gov't delivers environmental approval for Empire Energy's Beetaloo Carpentaria pilot gas play

BTH

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

BNL

Blue Star Helium sees approval for five more wells at 'Galactica/Pegasus' project in Colorado

There are more pages in this discussion • 13 more messages in this thread...

First 9 Last

Add SPL (ASX) to my watchlist

(20min delay)
Last 10.5¢		Change 0.000(0.00%)		Mkt cap ! $43.82M

Open	High	Low	Value	Volume
10.5¢	11.5¢	10.0¢	$110.6K	1.006M

Buyers (Bids)

No.	Vol.	Price($)
1	83046	10.5¢

Sellers (Offers)

Price($)	Vol.	No.
11.0¢	30000	1

View Market Depth

No.	Vol.	Price($)
1	6000	0.955
4	25073	0.950
1	3925	0.945
3	8847	0.940
1	10000	0.935

Price($)	Vol.	No.
0.960	4540	2
0.965	15000	1
0.970	13906	2
0.975	10000	1
0.980	19012	1

Last trade - 16.10pm 15/11/2024 (20 minute delay)

SPL (ASX) Chart

"as FDA have been clear they want another trial" Not true The...

Top Stories

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

HotCopper Highlights: Your most watched stocks for Week 46, 2024

InhaleRX gains approval for clinical trial to test non-opioid therapy for cancer pain

Week 46 Wrap: Copper hits 2mth low as Trump threatens net zero pace; US rally fades; HotCopper’s picks

CuFe sells its Crossroads gold royalty to Northern Star for $4M cash; says better than waiting for mine launch

Cyclone signs MOU with Vale for development of Iron Bear play

Banshee's historic trenches prove rich in antimony and gold for GDM

NT Gov't delivers environmental approval for Empire Energy's Beetaloo Carpentaria pilot gas play

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

Blue Star Helium sees approval for five more wells at 'Galactica/Pegasus' project in Colorado

Buyers (Bids)

Sellers (Offers)